Spots Global Cancer Trial Database for Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
Official Title: A Phase 1/2, Open-Label, Multicenter Study of GSK1363089Gin Adult Subjects With Hepatocellular Carcinoma
Study ID: NCT00920192
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the safety and tolerability of foretinib (also known as GSK1363089) when used in the treatment of patients with advanced hepatocellular carcinoma (liver cancer).
Detailed Description: The purpose of this study is to identify the maximum tolerated dose (MTD) of foretinib (also known as GSK1363089) when used in the treatment of patients with advanced hepatocellular carcinoma (liver cancer), and to assess the safety and tolerability of that dose in this patient population. The MTD will be identified during Phase I, by standard dose-escalation of foretinib. Then Phase II will assess the safety and tolerability of foretinib dosed at MTD.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Hong Kong, , Hong Kong
GSK Investigational Site, Tainan, , Taiwan
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Taipei, , Taiwan
GSK Investigational Site, Bangkok, , Thailand
GSK Investigational Site, Bangkok, , Thailand
GSK Investigational Site, Khon Kaen, , Thailand
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
